We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Events

27 Jan 2025 - 30 Jan 2025
15 Feb 2025 - 17 Feb 2025

“Lungs in a Box” Device Allows Surgeons to Rescue Potentially Viable Donor Lungs for Transplant

By HospiMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: The XPS is CE-marked and FDA approved for ex vivo lung perfusion of initially unacceptable donated lungs (Photo courtesy of XVIVO)
Image: The XPS is CE-marked and FDA approved for ex vivo lung perfusion of initially unacceptable donated lungs (Photo courtesy of XVIVO)

Due to COVID-19 and a rapidly expanding list of conditions for which lung transplantation can be lifesaving, the need for new organs is growing. However, with a global shortage of donated lungs, some patients die while on the waitlist. Out of all solid organs, lungs have the lowest utilization, with only one in five donated lungs getting transplanted. To help expand the donor pool, transplant surgeons are now using a ex vivo lung perfusion (EVLP) device designed to rescue potentially viable lungs and those initially deemed “unacceptable” for transplant.

XVIVO’s (Gothenburg, Sweden) EVLP device called XPS and nicknamed “lungs in a box” allows transplant surgeons to examine lungs outside the body. XPS is a fully integrated cardiac bypass system that includes all components. The XPS system is based on innovative technology from leading companies and includes a centrifugal pump (MAQUET CardioHelp), heater/cooler and ICU-ventilator (Hamilton). XPS was developed to provide transplantation teams with a consistent and easy-to-use method of performing EVLP in the hospital. The objective was to develop an automated perfusion system that would allow for standardization of EVLP, without interfering with the need for clinical flexibility.

The donor lungs are transported according to individual standard protocol, in a cooler box from the procurement site. The donor lungs are flushed thoroughly in PERFADEX Plus and then placed on the EVLP platform. After warming up according to a detailed protocol, it is up to the EVLP team to set preferred ventilation and perfusion strategies depending on the requirements of each donor lung. Integrated in-line perfusate gas monitors (PGM) enables for real-time trending of pH and pO2 during the entire EVLP procedure. The XPS also enables precise continuous trending of EVLP performance metrics.

The XPS is indicated for use in flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs during which time the ex vivo function of the lungs can be reassessed for transplantation. The XVIVO System (XPS) is intended for flushing and temporary continuous normothermic machine perfusion of isolated lungs, during which time the function of the lungs can be assessed for transplantation. The system was developed together with clinicians with extensive experience and knowledge from normothermic EVLP using STEEN Solution. Understanding the clinical needs and challenges transplant teams encounter in daily work, XPS facilitates clinical decision making and offers a flexible comprehensive platform for EVLP. XPS is specifically designed to facilitate X-ray while performing normothermic EVLP. XPS is the first FDA-approved EVLP technology on the market for ex vivo lung perfusion of initially unacceptable donated lungs and is also CE-marked.

“EVLP allows us to take donor lungs outside the body, attach them to a ventilator and make them clinically usable by treating infection, inflammation and edema – it’s visually stunning,” said Ankit Bharat, MD, chief of thoracic surgery at Northwestern Medicine and executive director of the Canning Thoracic Institute, who pioneered COVID-19 lung transplants in the US. “Because we were the first health system in the US to offer lung transplants for COVID-19 patients, our patient volume continues to increase, and we need every tool to help us get more patients transplanted. EVLP will give us the ability to fix lungs that don’t appear usable up front.”

Related Links:
XVIVO 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Mobile Power Procedure Chair
LeMans P360
New
Mattress Replacement System
Carilex DualPlus

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.